Evidence map›Paper›PMID 33445051›Full record

ArticleCellular immunology2021

IFN-γ

Sunita Yadav, Jay Prakash, Om Prakash Singh, Mallikarjuna Rao Gedda, Shashi Bhushan Chauhan, Shyam Sundar, Vikash Kumar Dubey

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sunita YadavSchool of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi 221005, India.
Jay PrakashSchool of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi 221005, India.
Om Prakash SinghDepartment of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India.
Mallikarjuna Rao GeddaInstitute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
Shashi Bhushan ChauhanInstitute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
Shyam SundarInstitute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
Vikash Kumar DubeySchool of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi 221005, India. Electronic address: vkdubey.bce@iitbhu.ac.in.
Banaras Hindu University · INIndian Institute of Technology BHU · IN

Funding

Visceral Leishmaniasis in Bihar State, IndiaP50AI074321 · NIAID · BANARAS HINDU UNIVERSITY · PI SUNDAR, SHYAM · 2007 to 2016
$6.4M
Visceral Leishmaniasis in Bihar State, IndiaU19AI074321 · NIAID · BANARAS HINDU UNIVERSITY · PI SUNDAR, SHYAM · 2017 to 2021
$2.8M
NIAID NIH HHS P50 AI074321NIAID NIH HHS U19 AI074321
6 · The paper itself

Abstract

Visceral leishmaniasis (VL) is a potentially fatal parasitic disease causing high morbidity and mortality in developing countries. Vaccination is considered the most effective and powerful tool for blocking transmission and control of diseases. However, no vaccine is available so far in the market for humans. In the present study, we characterized the hypothetical protein LDBPK_252400 of Leishmania donovani (LdHyP) and explored its prophylactic behavior as a potential vaccine candidate against VL. We found reduced hepato-splenomegaly along with more than 50% parasite reduction in spleen and liver after vaccination in mice. Protection in vaccinated mice after the antigen challenge correlated with the stimulation of antigen specific IFN-γ expressing CD4

Indexed as

AnimalsAntigens, ProtozoanCytokinesImmunity, CellularImmunizationLeishmania donovaniLeishmaniasis VaccinesLeishmaniasis, VisceralMacrophagesMiceMice, Inbred BALB CProtozoan ProteinsRecombinant ProteinsT-LymphocytesVaccinationAntigens, ProtozoanCytokinesLeishmaniasis VaccinesProtozoan ProteinsRecombinant ProteinsCD4/CD8+T cellsCFSEHypothetical proteinVaccineVisceral leishmaniasis

Identifiers

PMID33445051
PMCPMC7890570
OpenAlexW3117250409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.